[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350684-105":59,"doc-detail-350684-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","prediction-of-benefit-from-docetaxel-chemotherapy-for-hr-positive-breast-cancer-in-the-pacs-01-trial","Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial","","Adjuvant chemotherapy for hormone receptor–positive (HR+) breast cancer often uses taxanes, yet existing tests cannot clearly identify which patients benefit. This study evaluates whether the SETER/PR index, reflecting endocrinerelated transcriptional activity, predicts benefit from docetaxel in node-positive HR+ patients in the PACS-01 trial. SETER/PR and Recurrence Score (RS) were measured in 490 patients and analyzed against distant recurrence-free interval (DRFI) using Cox models with interaction terms. Results showed significant treatment interactions for continuous SETER/PR, with high SETER/PR (≥1.50) indicating worse outcomes with 3FEC+3D versus 6FEC.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prediction-of-benefit-from-docetaxel-chemotherapy-for-hr-positive-breast-cancer-in-the-pacs-01-trial/350684/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prediction-of-benefit-from-docetaxel-chemotherapy-for-hr-positive-breast-cancer-in-the-pacs-01-trial/350684.png","ImageObject",300,407,{"name":92,"@type":93},"PakDamar76","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of the PACS-01 trial analysis in this study?","Question",{"text":112,"@type":113},"To test whether the SETER/PR index could predict benefit from docetaxel chemotherapy in node-positive HR+ breast cancer patients enrolled in PACS-01.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were SETER/PR and Recurrence Score (RS) measured?",{"text":117,"@type":113},"SETER/PR was quantified using the QuantiGene Plex assay from RNA remaining after RS testing, and RS values were obtained for the 490 patients.",{"name":119,"@type":110,"acceptedAnswer":120},"Did RS predict differential benefit between chemotherapy arms?",{"text":121,"@type":113},"No. RS did not show predictive differential benefit either as a continuous variable or using the >25 threshold, based on non-significant interaction P values.",{"name":123,"@type":110,"acceptedAnswer":124},"When did docetaxel-containing treatment (3FEC+3D) perform worse?",{"text":125,"@type":113},"Exploratory analyses found that patients with SETER/PR ≥ 1.50 had worse outcomes with 3FEC+3D compared with continued anthracycline chemotherapy (6FEC).","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},350684,1790176334,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":46},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","The Breast 89 (2026) 104894  \nContents lists available at ScienceDirect  \nThe Breast  \njournal [homepage:](homepage: www.journals.elsevier.com/the-breast)[ www.journals.elsevier.com/the-breast](homepage: www.journals.elsevier.com/the-breast)  \n| Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial |  | |\n| --- | --- | --- |\n| Fr´ed´erique Penault-Llorcaa,* , Amelie Lusque b , Thomas Filleron b , Kevin Tranc, Lili Duc , Rick Baehnerd,e, Florence Dalenc f, Magali Lacroix-Triki g, Thomas Bacheloth, Fabrice Andrei, Pascal Boucher j , J´erˆome Lemonnierj , W. Fraser Symmansc \u003Cbr>a Department of Biopathology, Centre Jean Perrin, Universit´e Clermont Auvergne, INSERM, U1240 Imagerie Mol´eculaire et Strat´egies Th´eranostiques, Clermont Ferrand, F-63000, France\u003Cbr>b Biostatistics & Health Data Science Unit, University of Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, France c Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA d Exact Sciences, Madison, WI, USA\u003Cbr>e Department of Pathology, University of California, San Francisco, CA, USA\u003Cbr>f Department of Medical Oncology, Oncopole Claudius Regaud, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France g Department of Pathology, Institut Gustave Roussy, Villejuif, France\u003Cbr>h Department of Medical Oncology, Centre Leon Berard, Lyon, France i Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France j Unicancer, Paris, France |  |  |\n| A R T I C L E I N F O | A B S T R A C T\u003Cbr>Background: Adjuvant chemotherapy for hormone receptor–positive (HR+) breast cancer relies on taxanes, but existing tests do not identify which patients benefit from them. The SETER/PR index, a measure of endocrinerelated transcriptional activity in HR + tumors, recently predicted benefit from paclitaxel when low (\u003C0.75), but not for anthracycline-based therapy. We tested whether SET ER/PR could predict benefit from docetaxel in node-positive, HR + patients enrolled in the PACS-01 trial (docetaxel after fluorouracil–epirubicin–cyclophosphamide (3FEC+3D) versus 6FEC).\u003Cbr>Patients and methods: SET ER/PR index and Recurrence Score (RS) were obtained for 490 patients. SET ER/PR was quantified using the QuantiGene Plex assay from RNA remaining after RS testing. Pre-specified analyses assessed SET ER/PR as a continuous variable and using the predefined \u003C0.75 cut point, as well as continuous RS and the >25 cut point. The primary endpoint was distant recurrence-free interval (DRFI). Predictive value was assessed using Cox models including biomarker, treatment arm, and interaction term.\u003Cbr>Results: Continuous SET ER/PR demonstrated significant interaction with treatment on DRFI (P interaction = 0.028), whereas predefined \u003C0.75 cut point was not predictive (P interaction = 0.668). Exploratory analyses identified a cut point at 1.50 (P interaction = 0.013): patients with SET ER/PR ≥ 1.50 had worse outcomes with 3FEC+3D versus 6FEC (HR 3.16, 95%CI 1.28–7.85), while outcomes were similar between arms when SET ER/PR \u003C 1.50 (HR 0.83, 95%CI 0.51–1.35). RS did not predict differential benefit, either continuously (P interaction = 0.670) or at the >25 threshold (P interaction = 0.534).\u003Cbr>Conclusion: Including sequential docetaxel (3FEC+3D) was less effective than continued anthracycline chemotherapy (6FEC) when breast cancer had high endocrine-related transcriptional activity (i.e., SET ER/PR index ≥1.50).\u003Cbr>Trial registration: PACS-01. |  |\n| Presentations: Results from this study werepresented in part at the San Antonio Breast Cancer Symposium December 2025, in San Antonio, TX. |  |  |\n| Keywords: Docetaxel Anthracycline Chemotherapy Prediction Hormone receptor SET\u003Cbr>Index Recurrence score Menopausal Breast cancer Endocrine Transcription Activity |  |  |\n\n* Corresponding author. Centre Jean Perrin, Universit´e Clermont Auvergne, INSERM, U1240 Imagerie Mol´eculaire et Stra","cbCaitE2XTVIpB08","https://ap.wps.com/l/cbCaitE2XTVIpB08","pdf",2969967,"English","# Article information\n## Background\n## Patients and methods\n## Results\n## Conclusion\n## Trial registration\n## Keywords\n## Introduction","[{\"question\":\"What was the main goal of the PACS-01 trial analysis in this study?\",\"answer\":\"To test whether the SETER/PR index could predict benefit from docetaxel chemotherapy in node-positive HR+ breast cancer patients enrolled in PACS-01.\"},{\"question\":\"How were SETER/PR and Recurrence Score (RS) measured?\",\"answer\":\"SETER/PR was quantified using the QuantiGene Plex assay from RNA remaining after RS testing, and RS values were obtained for the 490 patients.\"},{\"question\":\"Did RS predict differential benefit between chemotherapy arms?\",\"answer\":\"No. RS did not show predictive differential benefit either as a continuous variable or using the \\u003e25 threshold, based on non-significant interaction P values.\"},{\"question\":\"When did docetaxel-containing treatment (3FEC+3D) perform worse?\",\"answer\":\"Exploratory analyses found that patients with SETER/PR ≥ 1.50 had worse outcomes with 3FEC+3D compared with continued anthracycline chemotherapy (6FEC).\"}]","Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial | PDF",1790090596]